U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Fallopian tube endometrioid tumor

MedGen UID:
274486
•Concept ID:
C1517113
•
Neoplastic Process
Synonyms: endometrium neoplasm of fallopian tube; Fallopian Tube Endometrioid Neoplasm; fallopian tube endometrioid neoplasm; Fallopian Tube Endometrioid Tumor; fallopian tube endometrioid tumor; fallopian tube endometrium neoplasm
 
Monarch Initiative: MONDO:0021576

Definition

A benign, borderline, or malignant epithelial tumor of the fallopian tube that is characterized by the presence of glands and/or cysts lined by neoplastic cells that resemble endometrial cells. [from NCI]

Professional guidelines

PubMed

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
New strategies in ovarian cancer treatment.
Lee JM, Minasian L, Kohn EC
Cancer 2019 Dec 15;125 Suppl 24(Suppl 24):4623-4629. doi: 10.1002/cncr.32544. PMID: 31967682Free PMC Article
Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.
Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM
Am Soc Clin Oncol Educ Book 2016;35:e247-57. doi: 10.1200/EDBK_158675. PMID: 27249730

Recent clinical studies

Etiology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.
Kurman RJ, Shih IeM
Am J Pathol 2016 Apr;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011. PMID: 27012190Free PMC Article
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD
Clin Cancer Res 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. PMID: 18698038

Diagnosis

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
Fallopian Tube Neoplasia and Mimics.
Kolin DL, Nucci MR
Surg Pathol Clin 2019 Jun;12(2):457-479. doi: 10.1016/j.path.2019.01.006. PMID: 31097111
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483

Therapy

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. PMID: 32359490Free PMC Article
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM
Clin Cancer Res 2014 Feb 1;20(3):764-75. Epub 2013 Nov 15 doi: 10.1158/1078-0432.CCR-13-2287. PMID: 24240112Free PMC Article

Prognosis

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake?
Höhn AK, Klagges S, Gläser A, Taubenheim S, Dornhöfer N, Einenkel J, Hiller GGR, Brambs CE, Horn LC
J Cancer Res Clin Oncol 2021 Mar;147(3):911-925. Epub 2020 Sep 11 doi: 10.1007/s00432-020-03387-4. PMID: 32915262
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM
Clin Cancer Res 2014 Feb 1;20(3):764-75. Epub 2013 Nov 15 doi: 10.1158/1078-0432.CCR-13-2287. PMID: 24240112Free PMC Article
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD
Clin Cancer Res 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. PMID: 18698038

Clinical prediction guides

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM
Clin Cancer Res 2014 Feb 1;20(3):764-75. Epub 2013 Nov 15 doi: 10.1158/1078-0432.CCR-13-2287. PMID: 24240112Free PMC Article
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD
Clin Cancer Res 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. PMID: 18698038

Recent systematic reviews

Laparoscopy versus laparotomy for the management of early stage endometrial cancer.
Galaal K, Donkers H, Bryant A, Lopes AD
Cochrane Database Syst Rev 2018 Oct 31;10(10):CD006655. doi: 10.1002/14651858.CD006655.pub3. PMID: 30379327Free PMC Article
Laparoscopy versus laparotomy for the management of early stage endometrial cancer.
Galaal K, Bryant A, Fisher AD, Al-Khaduri M, Kew F, Lopes AD
Cochrane Database Syst Rev 2012 Sep 12;(9):CD006655. doi: 10.1002/14651858.CD006655.pub2. PMID: 22972096

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...